Skip to content

Passive Plus Endocardial Pacing Leads Var. Models

by Siemens-Pacesetter, Inc.

510(k) K932892

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESP Substantially Equivalent — Postmarket Surveillance · Traditional NumberK932892 Date6 Jul 1994ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
DTB
Device Class
Class III
Regulation
21 CFR Part 870.3680
Advisory Committee
Cardiovascular
FDA Decision
SESP Substantially Equivalent — Postmarket Surveillance

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Passive Plus Endocardial Pacing Leads are classified as Permanent Pacemaker Electrodes, designed for endocardial implantation to deliver electrical pacing stimuli to the heart. These leads facilitate cardiac rhythm regulation by transmitting low-energy impulses to the right ventricle or atrium, ensuring proper heart function in patients with bradycardia or conduction disorders.

These leads are supplied sterile and intended for single-use implantation during cardiac procedures. They are regulated under FDA 510(k) clearance (K932892) and fall under the classification of Class 3 medical devices, governed by regulation 870.3680. Multiple model variants are available, each tailored for specific electrode configurations and pacing applications, with postmarket surveillance requirements noted in the submission.

Other devices from Siemens-Pacesetter, Inc.

Questions

AI-generated answers, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • Are these pacing leads reusable or intended for single-use only, and how should they be handled before implantation?

    These Passive Plus Endocardial Pacing Leads are sterile and intended for single-use only, as explicitly stated in the device description. They must be handled under sterile conditions and used immediately after opening to ensure patient safety and compliance with medical device regulations.

  • What types of pacing applications are these leads designed for, and where in the heart are they implanted?

    These leads are designed for endocardial implantation, meaning they are placed directly inside the heart chambers to deliver pacing stimuli. They are specifically tailored for right ventricular or atrial pacing to regulate cardiac rhythm in patients with bradycardia or conduction disorders, as described in the device’s purpose.

  • How many model variants are available, and are they differentiated by specific features or electrode configurations?

    Multiple model variants exist for these leads, each tailored to specific electrode configurations and pacing applications. While exact distinctions aren’t detailed in the provided data, the 18 listed FEI numbers (e.g., 3002618605, 2183787) suggest a range of designs to accommodate different clinical needs, such as lead length, coil type, or fixation mechanisms.

  • What regulatory pathway was followed for FDA clearance, and what class does this device fall under?

    The Passive Plus Endocardial Pacing Leads were cleared via the traditional 510(k) pathway (K932892) and are classified as Class 3 medical devices under FDA regulation 870.3680. This classification reflects their role in life-sustaining or supporting functions, requiring stringent oversight. The submission was reviewed by the Cardiovascular (CV) Advisory Committee in 1994.